Latest updates to clinical guidance for COVID-19 vaccines

Find the latest updates from the Australian Technical Advisory Group on Immunisation (ATAGI) on clinical guidance for administration of COVID-19 vaccines.

Date> Update Page
16 December 2022 Information updated regarding transport, storage and handling of vaccines Transporting storing and handling
9 December 2022 Recommendations and information on Comirnaty (Pfizer) vaccine for children aged 6 months to 4 years have been updated

Recommendations, Vaccines, dosage and administration, Adverse events, Vaccine information
Transporting storing and handling

28 November 2022 Recommendations and information on Comirnaty (Pfizer) Bivalent Original/Omicron BA.1 (Pfizer bivalent)

RecommendationsVaccines, dosage and administrationAdverse eventsVaccine information

24 October 2022 Recommendations and information on Comirnaty (Pfizer) vaccine as a booster dose for children aged 5 to 11 years

RecommendationsVaccines, dosage and administrationAdverse eventsVaccine information

5 October 2022 Recommendations and information on Spikevax (Moderna) Bivalent Original/Omicron BA.1 (Moderna bivalent) vaccine have been updated

RecommendationsVaccines, dosage and administration, Contraindications and precautionsAdverse events, Clinical features of COVID-19 disease, Vaccine information

Transporting storing and handling
23 September 2022 Latest information on myocarditis and pericarditis after COVID-19 vaccines COVID-19 vaccines and cardiac inflammation
21 September 2022 Precautions for Spikevax (Moderna) have been updated to include capillary leak syndrome Contraindications and precautions
31 August 2022 Recommendations and information on Spikevax (Moderna) vaccine for children aged 6 months to under 5 years have been updated

RecommendationsVaccines, dosage and administrationAdverse eventsVaccine information, Transporting storing and handling

31 August 2022 Recommendations and information on Nuvaxovid (Novavax) vaccine for adolescents aged 12 to 17 years have been updated

RecommendationsVaccines, dosage and administrationAdverse eventsVaccine information

31 August 2022 Table of medical conditions of increased risk of severe COVID-19 has been updated Clinical features of COVID-19 disease

7 July 2022

Updated recommendations for a winter dose of COVID-19 vaccine

Recommendations

1 July 2022

Recommendations on the use of Nuvaxovid (Novavax) boosters in people 18 years and older have been updated

Recommendations

15 June 2022

Recommendations for boosters in high-risk adolescents aged 12-15 years have been included

Recommendations

29 April 2022

The recommended interval between SARS-CoV-2 infection and vaccination has been updated

Recommendations

29 April 2022

Recommendations on vaccination after treatment with anti-SARS-CoV-2 monoclonal antibodies have been updated

Recommendations

29 April 2022

The recommended dosing schedule for Comirnaty (Pfizer) and Spikevax (Moderna) has been updated

Recommendations – recommended and variations on vaccine schedule

25 March 2022

Recommendations and evidence on the use of an additional booster dose have been included

Recommendations – Booster dose recommendationsVaccine information, Also see: ATAGI recommendations on the use of an additional winter booster dose

2 March 2022

Recommendations on the use of Nuvaxovid (Novavax) as a booster

Recommendations

28 February 2022

Recommendations on the use of Spikevax (Moderna) have been included

RecommendationsVaccine doses and administrationAdverse eventsVaccine information

23 February 2022

Recommendations on the use of Comirnaty (Pfizer) in adolescents aged 16 to 17 years have been included

RecommendationsVaccine information

23 February 2022

Information on the use of Nuvaxovid – the Novavax COVID-19 vaccine has been incorporated

RecommendationsVaccine doses and administrationContraindications and precautionsAdverse events

23 February 2022

Recommendations on the timing of booster doses following the primary course have been updated from 4 months to 3 months

Recommendations – B

24 January 2022

The time allowable for temporary deferral of vaccination following SARS-CoV-2 infection reduced from 6 month to 4 months

Recommendations – People with a past SARS-CoV-2 infection

17 January 2022

Severely immunocompromised children aged 5 – 11 years are recommended to receive a third primary dose of COVID-19 vaccine, in line with severely immunocompromised individuals aged 12 years and over.

Recommendations – People who are immunocompromised

Also see: ATAGI recommendations on the use of a 3rd primary dose of COVID-19 vaccine in severely immunocompromised individuals

ATAGI weekly update – 12 January 2022.

Last updated:

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.